

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INTAS PHARMACEUTICALS LTD.,
Petitioner

v.

JINA PHARMACEUTICALS, INC.,
Patent Owner

Case PGR2026-00015
Patent 12,245,997

DECLARATION OF SAYEM OSMAN

I, Sayem Osman, make the following Declaration pursuant to 28 U.S.C. § 1746:

1. I am a paralegal at the law firm of Groombridge, Wu, Baughman & Stone LLP.

2. I provide this Declaration in connection with the above-identified Petitioner's Petition for Post Grant Review of U.S. Patent No. 12,245,997 under 35 U.S.C.

§§321-329, 37 C.F.R. §42. Unless otherwise stated, the facts stated in this Declaration are based on my personal knowledge.

3. EX1001 hereto is a true and correct copy of U.S. Patent No. 12,245,997, which I retrieved on November 17, 2025 from the United States Patent and Trademark Office's Patent Center

(<https://ppubs.uspto.gov/external/print/pdfRedirectDownload/12245997?requestToken=eyJzdWliOiJkYjJlZWUxNy1mZDQ3LTQzOGUtYjEyYS03YzEzYmExYmE2NDAiLCJ2ZXliOiI4NmQ4ZGRlMi1mNGYxLTQ0N2MtYjM2Ni1iMTUyM2M2NzMwYjciLCJleHAiOiJB9>). An exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

4. EX1002 hereto is a true and correct copy of the file history for U.S. Patent No. 12,245,997, which I retrieved on November 17, 2025 from the United States Patent and Trademark Office's Patent Center

(<https://patentcenter.uspto.gov/applications/17226671/ifw/docs?application=>). An

exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

5. EX1004 hereto is a true and correct copy of an article by A. Ahmad et al., titled "*Endoxifen, a New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen*," 9 Clinical Translational Sci. 252 (2016), which I retrieved on December 9, 2025 from <https://pmc.ncbi.nlm.nih.gov/articles/PMC5350997/>. An exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

6. EX1005 hereto is a true and correct copy of an article by Robert M.A. Hirschfeld et al., titled "*Practice Guideline for the Treatment of Patients with Bipolar Disorder*," 159 Am. J. Psychiatry 1 (2002), which I retrieved on December 9, 2025 from <https://psychiatryonline.org/doi/pdf/10.1176/foc.1.1.64>. An exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

7. EX1006 hereto is a true and correct copy of an article by Ateeq Ahmad et al., titled "*Endoxifen: A New, Protein Kinase C Inhibitor to Treat Acute and Mixed Mania Associated with Bipolar I Disorder*," 23 Bipolar Disorders 595 (2021), which I retrieved on December 3, 2025 from <https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.13041>. An exhibit label and

page numbers have been added to the bottom of this document, but no other alterations have been made.

8. EX1008 hereto is a true and correct copy of an article by Ross J. Baldessarini et al., titled “*Bipolar Depression: Overview and Commentary*,” Harvard Review of Psychiatry 18(3): 143-157 (2010), which I retrieved on December 10, 2025 from https://journals.lww.com/hrpjournal/fulltext/2010/04000/bipolar_depression_overview_and_commentary.1.aspx. An exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

9. EX1009 hereto is an excerpted copy of American Psychiatric Association’s Manual titled “*Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*,” American Psychiatric Publishing (5th ed. 2013), which I retrieved on December 10, 2025 from https://ia800707.us.archive.org/15/items/info_munsha_DSM5/DSM-5.pdf. An exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

10. EX1010 is a true and correct copy of an article by Lena C. Quilty et al., titled “*The structure if the Montgomery-Asberg depression rating scale over the course of treatment for depression*,” Int. J. Methods Psychiatr. Res. 22(3): 175–184 (2013), which I retrieved on December 10, 2025 from <https://pmc.ncbi.nlm.nih.gov/articles/PMC6878407/pdf/MPR-22-175.pdf>. An

exhibit label and page numbers have been added to the bottom of this document, but no other alterations have been made.

11. I have been warned that willful false statements and the like are punishable by fine or imprisonment, or both. I make this declaration of my own personal knowledge, and all statements are true. If called to testify as to the truth of the matters stated herein, I could and would testify competently.

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 10th day of December, 2025 at Washington, D.C.



Sayem Osman